In meningiomas, elevated CDKN2A mRNA expression may serve as a biomarker of clinical aggressiveness, and deletion of pure-transgenic CDKN2A/B will result in a worse prognosis [32]. The gene discussed is CDKN2A; the disease is meningioma.